<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T05:12:46Z</responseDate>
  <request identifier="oai:figshare.com:article/34017727" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34017727</identifier>
        <datestamp>2026-09-28T17:53:12Z</datestamp>
        <setSpec>category_915</setSpec>
        <setSpec>category_7</setSpec>
        <setSpec>category_8</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_128</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Antigenic profiles of nucleoporins.&lt;/p&gt;</dc:title>
          <dc:creator>Rosita Asawa (25132843)</dc:creator>
          <dc:creator>Brittany Hazzard (14271698)</dc:creator>
          <dc:creator>Katie Ko (12809883)</dc:creator>
          <dc:creator>Kieran Tebben (14504872)</dc:creator>
          <dc:creator>John Tan (1865173)</dc:creator>
          <dc:creator>Tineke Cantaert (68002)</dc:creator>
          <dc:creator>Andrea Berry (6244949)</dc:creator>
          <dc:creator>Niraj Tolia (25132846)</dc:creator>
          <dc:creator>Jean Popovici (423629)</dc:creator>
          <dc:creator>David Serre (2815)</dc:creator>
          <dc:subject>Physical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Microbiology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Hematology</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>select vaccine candidates</dc:subject>
          <dc:subject>host immune system</dc:subject>
          <dc:subject>entire protein sequences</dc:subject>
          <dc:subject>develop new tools</dc:subject>
          <dc:subject>density peptide array</dc:subject>
          <dc:subject>analyses also revealed</dc:subject>
          <dc:subject>5 billion people</dc:subject>
          <dc:subject>analyzed antibody responses</dc:subject>
          <dc:subject>many uncharacterized proteins</dc:subject>
          <dc:subject>plasmodium vivax &lt;/</dc:subject>
          <dc:subject>clinical vivax malaria</dc:subject>
          <dc:subject>plasmodium &lt;/</dc:subject>
          <dc:subject>vivax &lt;/</dc:subject>
          <dc:subject>clinical importance</dc:subject>
          <dc:subject>antibody response</dc:subject>
          <dc:subject>wide perspective</dc:subject>
          <dc:subject>wide characterization</dc:subject>
          <dc:subject>unique pattern</dc:subject>
          <dc:subject>symptomatic individuals</dc:subject>
          <dc:subject>stage infections</dc:subject>
          <dc:subject>several nucleoporins</dc:subject>
          <dc:subject>naïve individuals</dc:subject>
          <dc:subject>malaria community</dc:subject>
          <dc:subject>infection worldwide</dc:subject>
          <dc:subject>important resource</dc:subject>
          <dc:subject>erythrocyte invasion</dc:subject>
          <dc:subject>data provide</dc:subject>
          <dc:subject>better detecting</dc:subject>
          <dc:subject>asymptomatic individuals</dc:subject>
          <dc:subject>antigens using</dc:subject>
          <dc:description>&lt;div&gt;&lt;p&gt;&lt;i&gt;Plasmodium vivax&lt;/i&gt; is the second most prevalent &lt;i&gt;Plasmodium&lt;/i&gt; species, with 2.5 billion people at risk of infection worldwide and around 10 million cases of clinical vivax malaria every year. Despite the clinical importance of this pathogen, little is known about the &lt;i&gt;P. vivax&lt;/i&gt; proteins recognized by the host immune system, which hinders our ability to select vaccine candidates or to develop efficient serological markers. To characterize immunogenic &lt;i&gt;P. vivax&lt;/i&gt; proteins, we designed a high-density peptide array containing 4.2 million peptides covering the entire protein sequences of all &lt;i&gt;P. vivax&lt;/i&gt; genes and analyzed antibody responses of infected and malaria-naïve individuals. We identified a total of 283 proteins that are commonly immunogenic in symptomatic individuals. These proteins included many proteins known to be involved in erythrocyte invasion, several nucleoporins, and many uncharacterized proteins that should be further investigated for their roles during blood-stage infections. These analyses also revealed a unique pattern of antibody response against PIR proteins in asymptomatic individuals that could be associated with protection against clinical vivax malaria. Overall, these data provide an agnostic and proteome-wide perspective on immunogenic &lt;i&gt;P. vivax&lt;/i&gt; proteins and constitute an important resource for the malaria community to develop new tools for better detecting and eliminating this important human pathogen.&lt;/p&gt;&lt;/div&gt;</dc:description>
          <dc:date>2026-09-28T17:53:52Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.ppat.1014621.s011</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Antigenic_profiles_of_nucleoporins_p_/34017727</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
